Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P07998

UPID:
RNAS1_HUMAN

ALTERNATIVE NAMES:
HP-RNase; RIB-1; RNase UpI-1; Ribonuclease 1; Ribonuclease A

ALTERNATIVE UPACC:
P07998; B2R589; D3DS06; Q16830; Q16869; Q1KHR2; Q6ICS5; Q9UCB4; Q9UCB5

BACKGROUND:
The Ribonuclease pancreatic enzyme, also referred to as RNase UpI-1 and Ribonuclease 1, is a pivotal player in the RNA world. It executes the cleavage of RNA adjacent to pyrimidine nucleotides, functioning on both strands of RNA. This endonuclease activity is vital for RNA turnover and the regulation of gene expression, underscoring its importance in cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionality of Ribonuclease pancreatic unveils potential pathways for therapeutic intervention. Given its critical role in RNA metabolism, targeting this enzyme could lead to innovative treatments for conditions associated with RNA dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.